

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAAXH1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS
patent records provide insights into related prior
art
NEWS 17 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:41:05 ON 28 FEB 2009

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.50	5.50

FILE 'REGISTRY' ENTERED AT 10:56:10 ON 28 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 FEB 2009 HIGHEST RN 1112548-05-6

DICTIONARY FILE UPDATES: 26 FEB 2009 HIGHEST RN 1112548-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\ahughes\My Documents\10509368(2).str

L1 STRUCTURE UPLOADED

=> s l1 sss sam

SAMPLE SEARCH INITIATED 10:56:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 83649 TO ITERATE

2.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1655766 TO 1690194
PROJECTED ANSWERS: 4068 TO 5968

L2 6 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 10:56:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1682782 TO ITERATE

59.4% PROCESSED 1000000 ITERATIONS 2759 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.15

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1682782 TO 1682782
PROJECTED ANSWERS: 4438 TO 4846

L3 2759 SEA SSS FUL L1

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.84	192.34

FILE 'REGISTRY' ENTERED AT 10:58:03 ON 28 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 FEB 2009 HIGHEST RN 1112548-05-6
DICTIONARY FILE UPDATES: 26 FEB 2009 HIGHEST RN 1112548-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	192.82

FILE 'CAPLUS' ENTERED AT 10:58:09 ON 28 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2009 VOL 150 ISS 10
FILE LAST UPDATED: 27 Feb 2009 (20090227/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 403 L3

=> s aging or wrinkles

230344 AGING

4860 WRINKLES

L5 233981 AGING OR WRINKLES

=> s l4 and l3

403 L3

L6 403 L4 AND L3

=> s l4 and l5

L7 5 L4 AND L5

=> d ibib hitstr abs l7 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1175767 CAPLUS

DOCUMENT NUMBER: 145:483731

TITLE: Bismuth subgallate and vasoconstrictor combinations for treating nosebleeds

INVENTOR(S): Binder, Jeffrey E.

PATENT ASSIGNEE(S): Binyarco, LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 4pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060252726	A1	20061109	US 2005-122894	20050505
AU 2006285404	A1	20070308	AU 2006-285404	20060503
CA 2606851	A1	20070308	CA 2006-2606851	20060503
WO 2007027236	A2	20070308	WO 2006-US16922	20060503
WO 2007027236	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1885347 A2 20080213 EP 2006-824731 20060503

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

JP 2008540434 T 20081120 JP 2008-510151 20060503

IN 2007KN04514 A 20080404 IN 2007-KN4514 20071123

PRIORITY APPLN. INFO.: US 2005-122894 A 20050505

WO 2006-US16922 W 20060503

IT 914467-56-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bismuth subgallate and vasoconstrictor combinations for treating nosebleeds)


RN 914467-56-4 CAPLUS

CN 1,3,2-Benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy-, mixt. with 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol (9CI) (CA INDEX NAME)

CM 1

CRN 1491-59-4


CMF C16 H24 N2 O



CM 2

CRN 99-26-3

CMF C7 H5 Bi O6



AB A composition and method for treating nosebleed, i.e., epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally. A paste composed of bismuth subgallate and oxymetazoline applied intranasally demonstrated hemostatic activity by inhibiting nosebleeds in patients treated with anticoagulant therapy.

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:301792 CAPLUS

DOCUMENT NUMBER: 144:324862

TITLE: Compositions and methods using 5-HT6 receptor antagonists and 5-HT2A receptor antagonists for treating cognitive disorders

INVENTOR(S): Bonhaus, Douglas William; Martin, Renee Sharon

PATENT ASSIGNEE(S): Roche Palo Alto LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060069094	A1	20060330	US 2005-241316	20051114
AU 2005291541	A1	20060413	AU 2005-291541	20050922
AU 2005291542	A1	20060413	AU 2005-291542	20050922
CA 2581921	A1	20060413	CA 2005-2581921	20050922
CA 2582273	A1	20060413	CA 2005-2582273	20050922
WO 2006037481	A1	20060413	WO 2005-EP10238	20050922
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
WO 2006037482	A2	20060413	WO 2005-EP10251	20050922
WO 2006037482	A3	20061019		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1797051	A1	20070620	EP 2005-796666	20050922
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
EP 1799306	A2	20070627	EP 2005-796070	20050922
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101031338	A	20070905	CN 2005-80033300	20050922
CN 101031554	A	20070905	CN 2005-80033306	20050922
JP 2008514662	T	20080508	JP 2007-533918	20050922
JP 2008514663	T	20080508	JP 2007-533919	20050922
BR 2005016754	A	20080916	BR 2005-16754	20050922
BR 2005016749	A	20080923	BR 2005-16749	20050922
US 20060106012	A1	20060518	US 2005-241632	20050930
US 7378415	B2	20080527		

MX 200703545	A	20070518	MX 2007-3545	20070326
NO 2007001616	A	20070425	NO 2007-1616	20070327
KR 2007046205	A	20070502	KR 2007-707141	20070329
KR 2007047844	A	20070507	KR 2007-707227	20070329
KR 875041	B1	20081219		
IN 2007CN01303	A	20070831	IN 2007-CN1303	20070329
IN 2007CN01308	A	20070831	IN 2007-CN1308	20070329
MX 200703911	A	20070521	MX 2007-3911	20070330
KR 2008109903	A	20081217	KR 2008-726939	20081103
PRIORITY APPLN. INFO.:			US 2004-614705P	P 20040930
			US 2004-630608P	P 20041124
			US 2005-707798P	P 20050812
			WO 2005-EP10238	W 20050922
			WO 2005-EP10251	W 20050922
			KR 2007-707141	A3 20070329


OTHER SOURCE(S): MARPAT 144:324862

IT 880544-35-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(5-HT6 and 5-HT2A receptor antagonists for treatment of cognitive disorders)

RN 880544-35-4 CAPLUS

CN Ethanone, 2-(4,5-dihydro-1H-imidazol-2-yl)-1-[2,3-dihydro-7-(phenylsulfonyl)-4H-1,4-benzoxazin-4-yl]- (CA INDEX NAME)



AB The invention discloses methods and pharmaceutical compns. comprising selective antagonists of the 5-HT6 receptor and 5-HT2A receptor which are useful for the treatment of cognitive disorders.

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:964827 CAPLUS

DOCUMENT NUMBER: 141:410926

TITLE: Preparation of dihydroimidazolylmethylindoles as α -1 adrenergic agonists.

INVENTOR(S): Dillon, Michael Patrick; Lin, Clara Jeou Jen; Moore, Amy Geraldine; O'Yang, Counde; Zhai, Yansheng

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 40 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 20040224973	A1	20041111	US 2004-841288	20040507
US 6979696	B2	20051227		
AU 2004235923	A1	20041118	AU 2004-235923	20040430
AU 2004235923	B2	20080124		
CA 2523253	A1	20041118	CA 2004-2523253	20040430
WO 2004099189	A1	20041118	WO 2004-EP4609	20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004010237	A	20060509	BR 2004-10237	20040430
EP 1660484	A1	20060531	EP 2004-739120	20040430
EP 1660484	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1784397	A	20060607	CN 2004-80012294	20040430
CN 100378097	C	20080402		
JP 2006525970	T	20061116	JP 2006-505343	20040430
RU 2313524	C2	20071227	RU 2005-138143	20040430
AT 406363	T	20080915	AT 2004-739120	20040430
MX 2005011841	A	20060126	MX 2005-11841	20051103
KR 751163	B1	20070822	KR 2005-721188	20051108
IN 2005CN02928	A	20070601	IN 2005-CN2928	20051109
PRIORITY APPLN. INFO.:			US 2003-469255P	P 20030509
			WO 2004-EP4609	W 20040430

OTHER SOURCE(S): MARPAT 141:410926


IT 791065-84-4P 791065-85-5P 791065-86-6P
 791065-87-7P 791065-88-8P 791065-89-9P
 791065-90-2P 791065-91-3P 791065-92-4P
 791065-93-5P 791065-94-6P 791065-95-7P
 791065-96-8P 791065-97-9P 791065-98-0P
 791065-99-1P 791066-00-7P 791066-01-8P
 791066-02-9P 791066-03-0P 791066-04-1P
 791066-07-4P 791066-08-5P 791066-09-6P
 791066-10-9P 791066-30-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of dihydroimidazolylmethylindoles as α -1 adrenergic agonists)

RN 791065-84-4 CAPLUS


CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-85-5 CAPLUS
CN 1H-Indole, 7-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-86-6 CAPLUS
CN 1H-Indole, 5-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-87-7 CAPLUS
CN 1H-Indole, 6-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-88-8 CAPLUS
CN 1H-Indole, 4-bromo-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-89-9 CAPLUS
CN 1H-Indole, 6-bromo-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-90-2 CAPLUS
CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(ethylsulfonyl)- (CA INDEX NAME)




RN 791065-91-3 CAPLUS
CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methoxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-92-4 CAPLUS
CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-fluoro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-93-5 CAPLUS
 CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 791065-94-6 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-4-fluoro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-95-7 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-fluoro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-96-8 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-1-

(methylsulfonyl)- (CA INDEX NAME)




RN 791065-97-9 CAPLUS

CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-98-0 CAPLUS

CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-4-methyl-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791065-99-1 CAPLUS


CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-methoxy-2-methyl-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-00-7 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-4-methoxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-01-8 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methoxy-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-02-9 CAPLUS
 CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-methoxy-4-methyl-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-03-0 CAPLUS
 CN 1H-Indole, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-04-1 CAPLUS
 CN 1H-Indole, 6-bromo-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-1-(methanesulfonyl)- (CA INDEX NAME)



RN 791066-07-4 CAPLUS
 CN 1H-Indole-1-carboxamide, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 791066-08-5 CAPLUS
 CN 1H-Indole-1-carboxamide, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 791066-09-6 CAPLUS
 CN 1H-Indole-1-carboxamide, 4-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-

N,N-dimethyl- (CA INDEX NAME)




RN 791066-10-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)




RN 791066-30-3 CAPLUS

CN 1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1-(methylsulfonyl)- (CA INDEX NAME)



GI



I

AB Title compds. [I; m = 0-4; X = C, N; Y = (substituted) (dihydro)imidazolyl; R1 = halo, haloalkyl, alkyl, OH, alkoxy, cyano, NO2, SONRa, NRaRb, (substituted) Ph, PhCH2, PhCH2O; n = 0-2; Ra-Rd, R3-R5 = H, alkyl; R2 = alkyl, (CH2)pNRcRd], were prepared for treatment of e.g. Alzheimer's disease, incontinence, bulimia, sinusitis, etc. (no data).

Thus, (6-bromo-5-fluoro-1-methanesulfonyl-1H-indol-3-yl)acetonitrile (preparation given) in EtOH at 0° was treated with HCl gas and the mixture was refrigerated for 72 h to give a residue which was refluxed 24 h with ethylenediamine in MeOH to give 55% 6-bromo-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-5-fluoro-1-methanesulfonyl-1H-indole.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:875271 CAPLUS

DOCUMENT NUMBER: 139:364930


TITLE: Preparation of N-(imidazolinylmethylaryl)alkanesulfonamides as α 1 adrenergic agonists
 INVENTOR(S): Dillon, Michael Patrick; Lin, Clara Jeou Jen; O'Yang, Counde; Zhang, Xiaoming
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091236	A1	20031106	WO 2003-EP3904	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483345	A1	20031106	CA 2003-2483345	20030415
AU 2003227623	A1	20031110	AU 2003-227623	20030415
EP 1501817	A1	20050202	EP 2003-725029	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009668	A	20050301	BR 2003-9668	20030415
CN 1646516	A	20050727	CN 2003-808923	20030415
CN 1296365	C	20070124		
JP 2005534628	T	20051117	JP 2003-587796	20030415
NZ 535823	A	20070727	NZ 2003-535823	20030415
RU 2318814	C2	20080310	RU 2004-134326	20030415
US 20030229130	A1	20031211	US 2003-421119	20030422
US 6756395	B2	20040629		
US 20040214875	A1	20041028	US 2004-823012	20040413
US 7407980	B2	20080805		
ZA 2004008169	A	20051018	ZA 2004-8169	20041008
MX 2004010315	A	20050608	MX 2004-10315	20041019
IN 2004CN02383	A	20070803	IN 2004-CN2383	20041020
NO 2004004531	A	20041119	NO 2004-4531	20041021
HK 1080463	A1	20070413	HK 2006-100195	20060105
PRIORITY APPLN. INFO.:			US 2002-374700P	P 20020423
			US 2002-378775P	P 20020508
			WO 2003-EP3904	W 20030415
			US 2003-421119	A1 20030422
OTHER SOURCE(S): MARPAT 139:364930				
IT 620604-49-1P 620604-61-7P 620604-66-2P				

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-(imidazolinylmethylaryl)alkanesulfonamides as α 1 adrenergic agonists)

RN 620604-49-1 CAPLUS


CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 620604-61-7 CAPLUS


CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 620604-66-2 CAPLUS

CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 620604-52-6P 620604-78-6P 620604-82-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of N-(imidazolinylmethylaryl)alkanesulfonamides as $\alpha 1$
 adrenergic agonists)
 RN 620604-52-6 CAPLUS
 CN Ethanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-78-6 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,5-dimethoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-82-2 CAPLUS
 CN Methanesulfonamide, N-[5-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 620604-50-4P, N-[4-(4,5-Dihydro-1H-imidazol-2-ylmethyl)-2,3-dihydrobenzofuran-7-yl]methanesulfonamide 620604-51-5P
 620604-53-7P 620604-60-6P 620604-63-9P
 620604-64-0P 620604-65-1P 620604-68-4P
 620604-69-5P 620604-71-9P 620604-75-3P
 620604-76-4P 620604-77-5P 620604-79-7P
 620604-80-0P 620604-81-1P 620604-83-3P
 620604-84-4P 620604-85-5P 620604-86-6P
 620604-87-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(imidazolinylmethylaryl)alkanesulfonamides as α 1 adrenergic agonists)
 RN 620604-50-4 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-7-benzofuranyl]- (CA INDEX NAME)




RN 620604-51-5 CAPLUS
 CN Methanesulfonamide, N-[3-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-53-7 CAPLUS
 CN 2-Propanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 620604-60-6 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxy-3-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-63-9 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-hydroxyphenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 620604-62-8
 CMF C11 H15 N3 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 620604-64-0 CAPLUS


CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 620604-65-1 CAPLUS

CN Ethanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxy-3-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 620604-68-4 CAPLUS

CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-hydroxyphenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 620604-67-3


CMF C11 H15 N3 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 620604-69-5 CAPLUS


CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 620604-71-9 CAPLUS

CN Methanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-75-3 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxy-5-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-76-4 CAPLUS
 CN Methanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-77-5 CAPLUS
 CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-79-7 CAPLUS
 CN Ethanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxyphenyl]- (CA INDEX NAME)



RN 620604-80-0 CAPLUS


CN Methanesulfonamide, N-[3-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 620604-81-1 CAPLUS


CN Methanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 620604-83-3 CAPLUS

CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methoxy-6-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-84-4 CAPLUS
CN Methanesulfonamide, N-[4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-ethoxyphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-85-5 CAPLUS
CN Methanesulfonamide, N-[2-bromo-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-86-6 CAPLUS
CN Ethanesulfonamide, N-[2-bromo-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 620604-87-7 CAPLUS
CN Ethanesulfonamide, N-[2-chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methylphenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

GI



I

AB Sulfonamides I [R1 = alkyl, (un)substituted NH2; R2 = H, alkyl; R3-R6 = H, halogen, alkyl, (un)substituted OH, NH2, SH; R3R4 = atoms required to complete a cycloalkyl or heterocyclic ring; R7 = H, alkyl, (un)substituted OH] were prepared for use as α 1 adrenergic agonists. Thus, Me 3-hydroxy-4-nitrobenzoate was O-allylated, rearranged to the 2-allyl derivative and oxidatively cyclized to Me 2-hydroxy-7-nitro-2,3-dihydrobenzofuran-4-carboxylate which was dehydrated, reduced to the amine, and converted to the methanesulfonamide. The ester group was then reduced to the alc., oxidized to the aldehyde, and treated with TosMIC to give the acetonitrile derivative which was cyclized with H2NCH2CH2NH2 to give I [R1 = Me, R2, R5-R7 = H, R3R4 = CH:CHO] which had pEC50 for α 1A/L agonist activity in cloned Chinese hamster ovarian cells of 6.52.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:610419 CAPLUS

DOCUMENT NUMBER: 139:149525

TITLE: Preparation of dihydroimidazolylmethylindoles and related compounds as α 1 A/L adrenergic receptor agonists for use against incontinence and other disorders

INVENTOR(S): Greenhouse, Robert; Jaime-Figueroa, Saul; Raptova, Lubica

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064387	A2	20030807	WO 2003-EP644	20030123

WO 2003064387 A3 20041202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2473803 A1 20030807 CA 2003-2473803 20030123
BR 2003007406 A 20041228 BR 2003-7406 20030123
EP 1501826 A2 20050202 EP 2003-714714 20030123
EP 1501826 B1 20060927

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
CN 1628113 A 20050615 CN 2003-803184 20030123
CN 100378095 C 20080402
JP 2005522427 T 20050728 JP 2003-564010 20030123
JP 4209332 B2 20090114
AT 340792 T 20061015 AT 2003-714714 20030123
ES 2271551 T3 20070416 ES 2003-714714 20030123
AU 2003218962 B2 20080925 AU 2003-218962 20030123
RU 2337909 C2 20081110 RU 2004-126613 20030123
US 20030220319 A1 20031127 US 2003-355588 20030131
US 6852726 B2 20050208
MX 2004007414 A 20041011 MX 2004-7414 20040730

PRIORITY APPLN. INFO.:

US 2002-353508P P 20020201
US 2002-418492P P 20021015
WO 2003-EP644 W 20030123

OTHER SOURCE(S): MARPAT 139:149525


IT 1070014-95-7 1070014-96-8 1070014-97-9
1070014-98-0 1070014-99-1 1070015-00-7
1070015-01-8 1070015-02-9

RL: PRPH (Prophetic)

(Preparation of dihydroimidazolylmethylindoles and related compounds as α 1 A/L adrenergic receptor agonists for use against incontinence and other disorders)


RN 1070014-95-7 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3,5-bis(methylsulfonyl)- (CA INDEX NAME)




RN 1070014-96-8 CAPLUS

CN 1H-Indole, 6-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(ethylsulfonyl)- (CA INDEX NAME)




RN 1070014-97-9 CAPLUS

CN 1H-Indole, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(4-morpholinesulfonyl)- (CA INDEX NAME)




RN 1070014-98-0 CAPLUS

CN 1H-Indole, 5-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 1070014-99-1 CAPLUS

CN 1H-Indole, 5-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 1070015-00-7 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-(4-fluorophenyl)-3-(methylsulfonyl)- (CA INDEX NAME)




RN 1070015-01-8 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-5-(phenylmethoxy)- (CA INDEX NAME)



RN 1070015-02-9 CAPLUS


CN 1H-Indole, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)



IT 573715-98-7P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-5-nitro-1H-indole 573716-01-5P, 7-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-03-7P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indol-5-ylamine 573716-34-4P, 2,5-Dichloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-50-4P, 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-2-(2-methoxyethyl)-1H-indole 573716-52-6P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-5-nitro-1H-indole-3-sulfonic acid amide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of dihydroimidazolymethylindoles and related compds. as α 1 A/L adrenergic receptor agonists for use against incontinence and other disorders)


RN 573715-98-7 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-5-nitro- (CA INDEX NAME)




RN 573716-01-5 CAPLUS

CN 1H-Indole, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-03-7 CAPLUS

CN 1H-Indol-5-amine, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-4,5-dihydro-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-34-4 CAPLUS


CN 1H-Indole, 2,5-dichloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)



RN 573716-50-4 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-(2-methoxyethyl)-3-(methanesulfonyl)- (CA INDEX NAME)



RN 573716-52-6 CAPLUS
 CN 1H-Indole-3-sulfonamide, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-nitro- (CA INDEX NAME)



IT 573715-68-1P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole 573715-78-3P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-6-methyl-1H-indole hydrochloride 573715-80-7P, 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole 573715-81-8P, 4-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole hydrochloride 573715-82-9P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-7-ethyl-3-methanesulfonyl-1H-indole 573715-83-0P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-5-methyl-1H-indole hydrochloride 573715-84-1P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2,5-dimethyl-1H-indole hydrochloride 573715-85-2P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-fluoro-3-methanesulfonyl-1H-indole hydrochloride 573715-86-3P, 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-ethanesulfonyl-1H-indole 573715-87-4P, 1-[1-(4,5-Dihydro-1H-imidazol-2-yl)ethyl]-3-methanesulfonyl-2-methyl-1H-indole 573715-88-5P, 1-[1-(4,5-Dihydro-1H-imidazol-2-yl)ethyl]-3-methanesulfonyl-1H-indole 573715-89-6P, 5-Chloro-1-[1-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-3-methanesulfonyl-2-methyl-1H-indole 573715-92-1P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-7-methyl-1H-indole 573715-96-5P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-3-methanesulfonyl-1H-indole 573715-97-6P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-5-methoxy-1H-indole 573715-99-8P, 7-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-00-4P, 5-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-04-8P, N-[1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-5-yl]methanesulfonamide 573716-05-9P, 6-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-08-2P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-


methanesulfonyl-1H-indole 573716-09-3P,
5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-10-6P, 7-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole 573716-14-0P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-7-fluoro-3-methanesulfonyl-2-methyl-1H-indole 573716-15-1P,
7-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-3-methanesulfonyl-1H-indole 573716-16-2P,
7-Trifluoromethyl-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-1H-indole 573716-17-3P,
2-[[7-Chloro-3-(methanesulfonyl)indol-1-yl]methyl]-4,5-dihydro-3H-imidazol-1-ium chloride 573716-24-2P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid dimethylamide 573716-28-6P,
2-[[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indol-3-yl]sulfonyl]ethanol 573716-40-2P,
[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl][3-(morpholin-4-yl)propyl]amine hydrochloride 573716-41-3P, [5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl][2-(morpholin-4-yl)ethyl]amine 573716-42-4P, N-[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl]ethane-1,2-diamine 573716-43-5P,
[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl]methylamine 573716-44-6P,
2-[[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl]amino]ethanol 573716-49-1P,
2-[5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-1H-indol-2-yl]ethanol 573716-56-0P,
5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-isopropyl-3-methanesulfonyl-1H-indole 573716-63-9P,
5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-ethyl-3-methanesulfonyl-1H-indole 573716-65-1P,
5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-propyl-1H-indole 573716-67-3P,
4-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3,4-dihydro-2H-thieno[3,2-b]indole 1,1-dioxide 573716-71-9P,
7-Bromo-4-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3,4-dihydro-2H-thieno[3,2-b]indole 1,1-dioxide 573716-73-1P,
4-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-7-methoxy-3,4-dihydro-2H-thieno[3,2-b]indole 1,1-dioxide 573716-75-3P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-6-methoxy-1H-indole 573716-80-0P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-7-methoxy-1H-indole 573716-82-2P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-4-methoxy-1H-indole 573716-84-4P, 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid dimethylamide 573716-90-2P,
6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid dimethylamide 573716-98-0P,
5-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid dimethylamide 573717-00-7P,
5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid dimethylamide 573717-02-9P,
6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid amide 573717-04-1P,
6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid methylamide 573717-06-3P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid amide 573717-08-5P, 6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid ethylamide 573717-10-9P,
1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic acid dimethylamide 573717-12-1P,
7-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid dimethylamide 573717-14-3P,
4-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic

acid dimethylamide 573717-16-5P,
 6-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic
 acid dimethylamide 573717-28-9P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic
 acid allylamide 573717-29-0P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(pyrrolidin-1-
 ylsulfonyl)-1H-indole 573717-30-3P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic
 acid N-(cyclopropylmethyl)amide 573717-31-4P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic
 acid N-(2-hydroxyethyl)-N-methylamide 573717-32-5P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic
 acid N-(2-hydroxyethyl)amide 573717-33-6P,
 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(morpholin-4-
 ylsulfonyl)-1H-indole 573717-34-7P,
 7-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-carboxylic
 acid amide 573717-35-8P,
 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid
 diallylamide 573717-36-9P,
 6-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic
 acid dimethylamide 573717-37-0P,
 6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid
 dimethylamide 573717-38-1P,
 6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonic acid
 methylamide 573717-39-2P,
 6-Bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(pyrrolidin-1-
 ylsulfonyl)-1H-indole
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of dihydroimidazolylmethylindoles and related
 compds. as α 1 A/L adrenergic receptor agonists for use against
 incontinence and other disorders)


RN 573715-68-1 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3-
 (methylsulfonyl)- (CA INDEX NAME)




RN 573715-78-3 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methyl-3-
 (methylsulfonyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 573715-80-7 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-81-8 CAPLUS
 CN 1H-Indole, 4-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 573715-82-9 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-ethyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-83-0 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-methyl-3-(methylsulfonyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 573715-84-1 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,5-dimethyl-3-(methylsulfonyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 573715-85-2 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-fluoro-3-(methylsulfonyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 573715-86-3 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(ethylsulfonyl)- (CA INDEX NAME)



RN 573715-87-4 CAPLUS
 CN 1H-Indole, 1-[1-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-88-5 CAPLUS
 CN 1H-Indole, 1-[1-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-89-6 CAPLUS

CN 1H-Indole, 5-chloro-1-[1-(4,5-dihydro-1H-imidazol-2-yl)ethyl]-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-92-1 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-96-5 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-97-6 CAPLUS


CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-methoxy-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573715-99-8 CAPLUS
 CN 1H-Indole, 7-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-00-4 CAPLUS
 CN 1H-Indole, 5-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-04-8 CAPLUS
 CN Methanesulfonamide, N-[1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-1H-indol-5-yl]- (CA INDEX NAME)




RN 573716-05-9 CAPLUS
 CN 1H-Indole, 6-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-08-2 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-
 (CA INDEX NAME)




RN 573716-09-3 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-10-6 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-14-0 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-fluoro-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-15-1 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-5-fluoro-3-(methylsulfonyl)- (CA INDEX NAME)



RN 573716-16-2 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-7-(trifluoromethyl)- (CA INDEX NAME)




RN 573716-17-3 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 573716-24-2 CAPLUS
 CN 1H-Indole-3-sulfonamide, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573716-28-6 CAPLUS

CN Ethanol, 2-[[5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-1H-indol-3-yl]sulfonyl]- (CA INDEX NAME)



RN 573716-40-2 CAPLUS


CN 1H-Indol-2-amine, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-N-[3-(4-morpholinyl)propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 573716-41-3 CAPLUS

CN 1H-Indol-2-amine, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 573716-42-4 CAPLUS

CN 1,2-Ethanediamine, N1- [5-chloro-1- [(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-1H-indol-2-yl]- (CA INDEX NAME)




RN 573716-43-5 CAPLUS

CN 1H-Indol-2-amine, 5-chloro-1- [(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-methyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-44-6 CAPLUS

CN Ethanol, 2- [[5-chloro-1- [(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-1H-indol-2-yl]amino]- (CA INDEX NAME)




RN 573716-49-1 CAPLUS


CN 1H-Indole-2-ethanol, 5-chloro-1- [(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-56-0 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-(1-methylethyl)-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-63-9 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-ethyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-65-1 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(methylsulfonyl)-2-propyl- (CA INDEX NAME)




RN 573716-67-3 CAPLUS
 CN 2H-Thieno[3,2-b]indole, 4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3,4-dihydro-, 1,1-dioxide (CA INDEX NAME)




RN 573716-71-9 CAPLUS
 CN 2H-Thieno[3,2-b]indole, 7-bromo-4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3,4-dihydro-, 1,1-dioxide (CA INDEX NAME)




RN 573716-73-1 CAPLUS
 CN 2H-Thieno[3,2-b]indole, 4-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3,4-dihydro-7-methoxy-, 1,1-dioxide (CA INDEX NAME)




RN 573716-75-3 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methoxy-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-80-0 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-7-methoxy-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-82-2 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-4-methoxy-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573716-84-4 CAPLUS
 CN 1H-Indole-3-sulfonamide, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573716-90-2 CAPLUS
 CN 1H-Indole-3-carboxamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573716-98-0 CAPLUS
 CN 1H-Indole-3-carboxamide, 5-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-00-7 CAPLUS
 CN 1H-Indole-3-carboxamide, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-02-9 CAPLUS
 CN 1H-Indole-3-carboxamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 573717-04-1 CAPLUS
 CN 1H-Indole-3-carboxamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-methyl- (CA INDEX NAME)




RN 573717-06-3 CAPLUS
 CN 1H-Indole-3-carboxamide, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 573717-08-5 CAPLUS
 CN 1H-Indole-3-carboxamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-ethyl- (CA INDEX NAME)



RN 573717-10-9 CAPLUS
 CN 1H-Indole-3-carboxamide, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-12-1 CAPLUS
 CN 1H-Indole-3-sulfonamide, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-14-3 CAPLUS

CN 1H-Indole-3-sulfonamide, 4-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-16-5 CAPLUS

CN 1H-Indole-3-carboxamide, 6-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 573717-28-9 CAPLUS

CN 1H-Indole-3-sulfonamide, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-2-propen-1-yl- (CA INDEX NAME)




RN 573717-29-0 CAPLUS

CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(1-pyrrolidinylsulfonyl)- (CA INDEX NAME)




RN 573717-30-3 CAPLUS

CN 1H-Indole-3-sulfonamide, 5-chloro-N-(cyclopropylmethyl)-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 573717-31-4 CAPLUS

CN 1H-Indole-3-sulfonamide, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 573717-32-5 CAPLUS

CN 1H-Indole-3-sulfonamide, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 573717-33-6 CAPLUS

CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(4-morpholynylsulfonyl)- (CA INDEX NAME)




RN 573717-34-7 CAPLUS

CN 1H-Indole-3-carboxamide, 7-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 573717-35-8 CAPLUS

CN 1H-Indole-3-sulfonamide, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-N,N-di-2-propen-1-yl- (CA INDEX NAME)




RN 573717-36-9 CAPLUS

CN 1H-Indole-3-sulfonamide, 6-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-
N,N-dimethyl- (CA INDEX NAME)




RN 573717-37-0 CAPLUS

CN 1H-Indole-3-sulfonamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-
N,N-dimethyl- (CA INDEX NAME)




RN 573717-38-1 CAPLUS

CN 1H-Indole-3-sulfonamide, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-
N-methyl- (CA INDEX NAME)




RN 573717-39-2 CAPLUS


CN 1H-Indole, 6-bromo-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-(1-
pyrrolidinylsulfonyl)- (CA INDEX NAME)




IT 573717-40-5, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-6-methoxy-2-methyl-1H-indole 573717-41-6, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2,5-dimethyl-1H-indole 573717-42-7, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3-(methanesulfonyl)-2-methyl-7-trifluoromethyl-1H-indole 573717-43-8, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3,4-bis(methanesulfonyl)-2-methyl-1H-indole 573717-44-9, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-3,6-bis(methanesulfonyl)-2-methyl-1H-indole
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug candidate; preparation of dihydroimidazolylmethylindoles and related compds. as $\alpha 1$ A/L adrenergic receptor agonists for use against incontinence and other disorders)
 RN 573717-40-5 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methoxy-2-methyl-3-(methylsulfonyl)- (CA INDEX NAME)



RN 573717-41-6 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,5-dimethyl-3-(methylsulfonyl)- (CA INDEX NAME)




RN 573717-42-7 CAPLUS
 CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3-(methylsulfonyl)-7-(trifluoromethyl)- (CA INDEX NAME)




RN 573717-43-8 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3,4-bis(methylsulfonyl)- (CA INDEX NAME)



RN 573717-44-9 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2-methyl-3,6-bis(methylsulfonyl)- (CA INDEX NAME)




IT 596807-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydroimidazolylmethylinroles and related compds. as α 1 A/L adrenergic receptor agonists for use against incontinence and other disorders)

RN 596807-97-5 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-methyl-3-(methylsulfonyl)- (CA INDEX NAME)



IT 573716-33-3P, 5-Chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-[2-[(tetrahydropyran-2-yl)oxy]ethanesulfonyl]-1H-indole

573717-22-3P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole

573717-24-5P, 1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-

sulfonic acid monohydrochloride 573717-26-7P,

1-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-1H-indole-3-sulfonyl chloride monohydrochloride


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of dihydroimidazolylmethylinroles and related compds. as
α1 A/L adrenergic receptor agonists for use against incontinence
and other disorders)


RN 573716-33-3 CAPLUS

CN 1H-Indole, 5-chloro-1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-[[2-
[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]sulfonyl]- (CA INDEX NAME)




RN 573717-22-3 CAPLUS

CN 1H-Indole, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)



RN 573717-24-5 CAPLUS


CN 1H-Indole-3-sulfonic acid, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 573717-26-7 CAPLUS

CN 1H-Indole-3-sulfonyl chloride, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

GI



AB This invention relates to indoles (shown as I; variables defined below; e.g. 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole) that are $\alpha 1$ receptor agonists, preferably $\alpha 1$ A/L receptor agonists; or individual isomers, racemic or nonracemic mixts. of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compns. containing such compds., their preparation and their use as therapeutic agents, e.g. incontinence, sexual dysfunction, nasal congestion, sinusitis, otitis, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, eating disorders, obesity, bulimia, and anorexia. A number of pharmaceutical compns. are described. EC_{50} and intrinsic agonist activity values for 9 examples of I are tabulated. Nineteen example preps. of I are included. For example, 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole was prepared in 5 steps: (1) to prepare (2-methyl-1H-indol-3-yl)dimethylsulfonium chloride N-chlorosuccinimide (29.35 mmol) was suspended in dichloroethane (40 mL) under a N_2 atmosphere and cooled to -10° using an ice-salt-acetone bath. Di-Me sulfide (3 mL) was slowly added with stirring over a period of .apprx.5 min. The mixture was stirred at this temperature for 10 min beyond the addition, at which time the ice-salt-acetone bath was replaced by a dry-ice acetone bath and the temperature was lowered to -50° . To this solution was added 2-methylindole (29.35 mmol) dissolved in dichloroethane (40 mL) slowly with stirring. The reaction mixture was stirred while allowing the temperature to reach 20° over about an hour. To prepare 2-methyl-3-methylthio-1H-indole (2-methyl-1H-indol-3-yl)dimethylsulfonium chloride (2 g) was placed under vacuum in a flask connected to a tube and distillation bulb receiver and gently warmed with a heat gun until bubbling of gas commenced. The sample was heated intermittently until the bubbling ceased and no more product distilled over. To prepare (2-methyl-3-methylsulfanylidol-1-yl)acetonitrile (1.05 g

of oil) 2-methyl-3-methylthio-1H-indole (6.21 mmol) was dissolved in toluene (25 mL). To this solution was added bromoacetonitrile (7.42 mmol) and Bu4NBr (1 g). With stirring, a solution of 4 g NaOH dissolved in 4 mL H2O was added. After 30 min another few drops of bromoacetonitrile were added to complete the reaction. After 30 min more, the stirring was stopped and the reaction was allowed to stand overnight at room temperature To prepare [3-(methanesulfonyl)-2-methylindol-1-yl]acetonitrile (1.01 g) (2-methyl-3-methylsulfanylindol-1-yl)acetonitrile (4.86 mmol) was dissolved in CH2Cl2 (50 mL) and cooled in an ice bath to 0°. At this temperature m-chloroperoxybenzoic acid (.apprx.77% , 2.4 g) was added in portions. The ice bath was removed and the reaction mixture was allowed to reach room temperature while stirring for 1 h. To prepare 1-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-3-methanesulfonyl-2-methyl-1H-indole (520 mg) N-[3-(methanesulfonyl)-2-methylindol-1-yl]acetonitrile (2.014 mmol) was mixed with ethylenediamine (2 mL) and 2 drops of CS2 was added carefully. The flask was flushed with N2 and placed in an oil bath preheated to 150°. The bath was maintained at 140-150° for a total of 75 min. For I: X is -S(O)n- or -C(O)-; A is (C1-6)-alkyl, aryl, heteroaryl, hydroxy(C1-6)-alkyl, or -(CH2)p-NR_aR_b; R₁, R₂, R₃, and R₄ each independently = H, halogen, halogen(C1-6)-alkyl, (C1-6)-alkyl, hydroxy, (C1-6)-alkoxy, (C1-6)-alkylthio, (C1-6)-alkylsulfinyl, (C1-6)-alkylsulfonyl, (C1-6)-alkylsulfonylamino, (C1-6)-alkylaminosulfonyl, cyano, nitro, -NR_aR_b, Ph, benzyl, and benzyloxy, wherein said Ph rings are (un)substituted with (C1-6)-alkyl, halogen, cyano, nitro, halogen(C1-6)-alkyl, or (C1-6)-alkoxy. R₅ is H, (C1-6)-alkyl, (C1-6)-alkoxy, (C1-6)-alkoxyalkyl, (C1-6)-alkylthio, (C1-6)-alkylsulfinyl, (C1-6)-alkylsulfonyl, hydroxy(C1-6)-alkyl, hydroxy(C1-6)-alkylamino, halogen, halogen(C1-6)-alkyl, cyano, -NR_aR_b, -NRC-(C1-6)-alkylene-NR_aR_b, or R₅ and A together form a C2-C3 alkylene radical; R₆ is H or (C1-6)-alkyl; R' and R'' each independently is H or (C1-6)-alkyl; R_a, R_b, and R_c each independently = H, (C1-6)-alkyl, hydroxy(C1-6)-alkyl, (C2-6)-alkenyl, (C3-6)-cycloalkyl(C1-6)-alkyl and arylsulfonyl, or R_a and R_b together with the N they are attached may also form a 5- to 7-membered nonarom. heterocyclic ring optionally incorporating an addnl. ring heteroatom = N, O, or S; m is 1 or 2; n = 0-2 with the proviso that when n is 0, R₅ is not -NR_aR_b; and p = 0-2.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.68	229.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.10	-4.10

FILE 'STNGUIDE' ENTERED AT 11:03:09 ON 28 FEB 2009
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Feb 20, 2009 (20090220/UP).

=>

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 10:41:05 ON 28 FEB 2009)

FILE 'REGISTRY' ENTERED AT 10:56:10 ON 28 FEB 2009

L1 STRUCTURE UPLOADED
L2 6 S L1 SSS SAM
L3 2759 S L1 SSS FUL

FILE 'REGISTRY' ENTERED AT 10:58:03 ON 28 FEB 2009

FILE 'CAPLUS' ENTERED AT 10:58:09 ON 28 FEB 2009

L4 403 S L3
L5 233981 S AGING OR WRINKLES
L6 403 S L4 AND L3
L7 5 S L4 AND L5

FILE 'STNGUIDE' ENTERED AT 11:03:09 ON 28 FEB 2009